Analysts expect Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings of ($1.06) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.00) and the lowest estimate coming in at ($1.17). Adamas Pharmaceuticals posted earnings per share of ($0.66) in the same quarter last year, which indicates a negative year over year growth rate of 60.6%. The company is scheduled to issue its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($3.88) per share for the current fiscal year, with EPS estimates ranging from ($4.07) to ($3.77). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.79) to ($1.26). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The company’s revenue for the quarter was down 90.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.78) EPS.

A number of research analysts have recently commented on the stock. Mizuho restated a “buy” rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub cut shares of Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 17th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Finally, JMP Securities reiterated an “outperform” rating and set a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Adamas Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $32.00.

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) traded up 4.82% during midday trading on Friday, hitting $21.53. 1,175,386 shares of the stock were exchanged. The firm has a 50 day moving average of $18.00 and a 200-day moving average of $17.19. The stock’s market cap is $484.73 million. Adamas Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $22.58.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/16/1-06-eps-expected-for-adamas-pharmaceuticals-inc-adms-this-quarter.html.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 731,041 shares of company stock worth $12,476,149. 29.00% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in ADMS. Wells Fargo & Company MN boosted its holdings in shares of Adamas Pharmaceuticals by 28.4% in the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Adamas Pharmaceuticals by 2.4% in the 1st quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock valued at $1,152,000 after buying an additional 1,563 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Adamas Pharmaceuticals by 153.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Adamas Pharmaceuticals in the 1st quarter valued at about $1,750,000. Finally, Trexquant Investment LP bought a new stake in shares of Adamas Pharmaceuticals in the 1st quarter valued at about $287,000. Institutional investors and hedge funds own 69.24% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.